Study of an mRNA treatment for autoimmune cytopenias
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new mRNA-based treatment for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The treatment aims to lower the immune attack and raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary immune thrombocytopenia (ITP).
- Your ITP has not improved with standard treatments or has come back after treatment.
- You do not have an active infection.
- You do not have heart failure, reduced kidney function, or liver problems.
- You have no known allergy to mRNA vaccines or similar products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called universal allogeneic CAR T-cell therapy (QT-019C) for adults with severe, hard-to-treat immune thrombocytopenia (ITP). It aims to see if targeting CD19 and BCMA on immune cells can safely improve platelet counts.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests a new mRNA treatment that targets a protein called CD19 on immune cells. It may help people with severe autoimmune diseases like lupus, ITP, or AIHA when other treatments haven't worked.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.